Skip to content

PTSD: all studies

Page 168 of 211: studies 1,671 to 1,680 of 2,103, newest first. Back to the PTSD overview

Research

N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine

Human Psychopharmacology: Clinical and Experimental February 17, 2022 Edward James, Joachim Keppler, Ben Sessa et al. 41 citations

Abstract Objective Reports have indicated possible uses of ayahuasca for the treatment of conditions including depression, addictions, post‐traumatic stress disorder, anxiety and specific psychoneuroendocrine immune system pathologies. The article assesses potential ayahuasca and N,N‐dimethyltryptamine (DMT) integration with contemporary healthcare. The review also seeks to provide a summary of...

A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults

Journal of Psychopharmacology February 15, 2022 Jessica L Maples-Keller, Seth D. Norrholm, Mark Burton et al. 53 citations

Background: Fear conditioning and extinction are well-characterized cross-species models of fear-related posttraumatic stress disorder (PTSD) symptoms, and recent animal data suggest that 3,4-methylenedioxymethamphetamine (MDMA) enhances fear extinction retention. Aims: This study investigated the effect of MDMA on fear learning, extinction training, and retention in healthy humans. Methods:...

Real-world patient characteristics, treatment patterns, efficacy and safety of intramuscular ketamine treatment: a retrospective cohort study

Research Square February 14, 2022 Sachin Ahuja, Madeline Brendle, Leo Smart et al. 2 citations preprint

Abstract Background Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics. However, a characterization of the outpatient population receiving IM ketamine treatment, and an evaluation of the real-world efficacy and safety of long-term...

Neurovascular Uncoupling: Multimodal Imaging Delineates the Acute Effects of MDMA

bioRxiv Preprint Server February 14, 2022 Tudor M. Ionescu, Mario Amend, Tadashi Watabe et al. 1 citation preprint

Psychedelic compounds have attracted increasing interest in recent years due to their therapeutic potential for psychiatric disorders. Methylenedioxymethamphetamine (MDMA) is currently being investigated in clinical trials to treat post-traumatic stress disorder. To understand the acute effects of psychedelic drugs in vivo, functional MR imaging (fMRI) has been widely used in recent years....

The frontiers of new psychedelic therapies: A survey of sociological themes and issues

Sociology Compass February 1, 2022 Timothy Andrews, Katie Wright 37 citations

Abstract Psychedelic compounds are on the cusp of being approved by medical regulators for treatment‐resistant mental health disorders. Following promising clinical trials, and as rates of mental ill health rise globally, psychedelic medicine presents a new paradigm for treating depression, anxiety, addiction and post‐traumatic stress disorder. The novelty of psychedelic therapies, the cultural...

DOI: 10.1111/soc4.12959 (opens in new tab) Mental health Context archaeology Field mathematics Conceptualization +3

Mind/No-Mind

Snapshots from Home January 25, 2022 K.M. Fierke

This chapter moves to an exploration of the relationship between emptiness and ‘no mind’. Mindfulness is usually associated with some form of meditation. The latter is also central to Eastern traditions of fighting. The chapter connects self to mind and action while also revealing how something formless, that is, no-mind, can express intention and action, and how this action, embedded in a...

Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database

Frontiers in Psychiatry January 24, 2022 Tigran Makunts, Lisa Jerome, Ruben Abagyan et al. 19 citations

3,4-Methylenedioxymethamphetamine (MDMA), is investigated as a treatment for post-traumatic stress disorder and other anxiety-related conditions in multiple placebo-controlled and open label studies. MDMA-assisted therapy is projected for approval by the United States Food and Drug Administration (FDA) and other regulatory agencies worldwide within the next few years. MDMA is a monoamine...

DOI: 10.3389/fpsyt.2021.824288 (opens in new tab) Full text (opens in new tab) Serotonin syndrome Faers database Surveillance system

Psychedelics hold promise for primary care research

Family Practice January 24, 2022 James Bailey Sanford

Dear Editor, We are in the midst of a so-called “psychedelic renaissance,” a time of renewed interest in the therapeutic potential of psychoactive drugs such as psilocybin, mescaline, and lysergic acid diethylamide. When they first emerged as topics of academic interest in the mid-20th century, these substances were greeted with exuberance for their apparent panacea-like effects in treating a...

Identifying alternative mental health interventions: a systematic review of randomized controlled trials of chanting and breathwork

Journal of Spirituality in Mental Health January 22, 2022 S. Malviya, P. Meredith, Barbra Zupan et al.

ABSTRACT This systematic review of randomized controlled trials investigated the effects of two religious/spiritual (R/S) practices (breathwork and chanting) on mental health outcomes (depression, anxiety, stress, and post-traumatic stress disorder (PTSD) symptoms). After registering with PROSPERO (CRD42020136645), a systematic search of four major databases (CINAHL, MEDLINE, PsycINFO, and...

Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity.

Biochemistry January 21, 2022 David E. Olson 121 citations

In addition to producing profound subjective effects following acute administration, psychedelic compounds can induce beneficial behavioral changes relevant to the treatment of neuropsychiatric disorders that last long after the compounds have been cleared from the body. One hypothesis with the potential to explain the remarkable enduring effects of psychedelics is related to their abilities to...